Skip to content
DE

Melanotan IAlias and product context

Melanotan I is a research name associated with afamelanotide. The regulated implant for a rare light-sensitivity disorder and a vial marketed for tanning have different uses and require separate evidence.

What is Melanotan I?

Melanotan I is a research name associated with afamelanotide. The clinical implant used for erythropoietic protoporphyria and a vial marketed for tanning may refer to the same intended molecule but are not interchangeable treatments.

How it works

Afamelanotide acts on melanocortin signalling involved in eumelanin production. The resulting pigment response is relevant to light tolerance as well as skin colour.

Effects studied

Light tolerance in erythropoietic protoporphyria

Afamelanotide trials studied a rare condition in which light can trigger severe pain. The clinically relevant outcome was tolerance to light in that condition, rather than cosmetic tanning in healthy users. 2

Evidence: Clinical trials of a defined implant and medical indication.

What does the evidence show?

The archive contains pigmentation research and afamelanotide trials. Neither establishes that every product advertised as Melanotan I is equivalent to the studied preparation.

The shared biological idea

Afamelanotide acts on melanocortin signalling associated with eumelanin production. That pigment response explains the interest in tanning and light tolerance. It does not by itself resolve whether a particular product produces a worthwhile clinical benefit with acceptable risks.

Why the medical evidence is narrower

The regulated implant was studied in erythropoietic protoporphyria, where light can trigger severe pain. The important outcome is improved tolerance to light in that condition. A cosmetic user seeking darker skin is asking a different question, with a different balance of potential benefit and harm. 2

What a vial label cannot establish

A matching compound name does not establish concentration, sustained release, impurity profile or sterility. Nor does it show that a supplier’s material has been compared with the implant. These differences remain relevant even if the starting chemical sequence is intended to be identical.

Pigmentation still needs context

Darker skin and changes in existing moles can make visual monitoring more difficult. A tanning effect does not remove the need for sun protection or attention to new skin changes. The afamelanotide page describes the medical research; evidence for that treatment cannot simply be applied to a different product.

Safety & status

Pigmentation and changes in moles need appropriate monitoring. A tanning effect does not remove the need for ultraviolet protection; online vials also have separate quality and sterility questions.

Country and product status

This introduction describes the molecule and its research context. Product availability, approved indications and eligibility in Germany and Switzerland require a current local product check; they are not established by an overseas study or an online listing.

Frequently asked questions

Is a Melanotan I vial equivalent to the clinical implant?

A matching name does not establish concentration, release characteristics, purity or sterility. Equivalence needs evidence for the preparation.

How does it differ from Melanotan II?

They are different molecules. Evidence for afamelanotide should not be used as evidence for Melanotan II.

Sources

This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.

  1. Melanotan I: pubmed.ncbi.nlm.nih.gov reference Research reference · Retained archive reference; not independently checked for this draft.
  2. Melanotan I: pubmed.ncbi.nlm.nih.gov reference Research reference · Retained archive reference; not independently checked for this draft.
  3. Melanotan I: paper 10.1016/j.jpba.2012.11.040 Research reference · Retained archive reference; not independently checked for this draft.
Research provenance

This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.